Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thyrocare Technologies's EBIT per Share for the
three
months ended in Jun. 2026 was ₹4.30.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹14.69.
During the past 12 months, the average EBIT per Share Growth Rate of Thyrocare Technologies was 48.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 34.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 2.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 4.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Thyrocare Technologies's EBIT per Share or its related term are showing as below:
NSE:THYROCARE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -15.8 Med: 13.1 Max: 34.1
Current: 34.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Thyrocare Technologies was 34.10% per year. The lowest was -15.80% per year. And the median was 13.10% per year.
NSE:THYROCARE's 3-Year EBIT Growth Rate is ranked better than 72.56% of 164
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs NSE:THYROCARE: 34.10
Thyrocare Technologies (NSE:THYROCARE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Thyrocare Technologies EBIT per Share Related Terms
Thyrocare Technologies EBIT per Share Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies (NSE:THYROCARE) has a EBIT per Share of ₹14.69 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Thyrocare Technologies and its competitors. According to the industry distribution chart, Thyrocare Technologies ranks #45 out of 164 companies in the Medical Diagnostics & Research industry, placing it in the top 27.4%.
Is Thyrocare Technologies' EBIT per Share too high?
Thyrocare Technologies' current EBIT per Share is ₹14.69. Based on the distribution chart, Thyrocare Technologies ranks #45 out of 164 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Thyrocare Technologies has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #45 out of 164 companies for EBIT per Share. This puts Thyrocare Technologies in the upper half of its industry. The industry median EBIT per Share is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current EBIT per Share is ₹14.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹414.13, compared to a current price of ₹579.70 — trading 40% above its estimated fair value. The current EBIT per Share is ₹14.69. Thyrocare Technologies' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current EBIT per Share is ₹14.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹579.70 is trading 40% above its estimated GF Value™ of ₹414.13.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
EBIT per Share: ₹14.69
GF Value™: ₹414.13 vs. price of ₹579.70 (40% above fair value)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
89GF Score
Get the complete analysis for NSE:THYROCARE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
